{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-048557","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.405535+00:00","generated_at":"2026-05-17T00:35:53.286075+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Esperion appoints John Harlow as Chief Commercial Officer effective Nov 17, 2025","bullets":["John Harlow appointed CCO; base salary $535,000, target bonus 45%, sign-on bonus $35,000.","Equity grants: option for 380,000 shares and 424,536 RSUs, vesting over four years.","Harlow previously CCO at Melinta Therapeutics, where revenue nearly doubled (~85% growth from 2020 to 2024).","He reports to CEO Sheldon Koenig and joins Esperion's Executive Leadership Team.","Harlow brings over 20 years of pharma commercial leadership from Melinta, Baudax Bio, Endo, Pfizer, and Novartis."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-048557","json":"https://secwatch.observer/filing/0001628280-25-048557.json","markdown":"https://secwatch.observer/filing/0001628280-25-048557.md","text":"https://secwatch.observer/filing/0001628280-25-048557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025048557/0001628280-25-048557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025048557/espr-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:35:53.286075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}